C4 Therapeutics, Inc. Increase (Decrease) in Prepaid Expense and Other Assets
C4 Therapeutics, Inc. (CCCC) reported Increase (Decrease) in Prepaid Expense and Other Assets of $1.54 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-08-11
- C4 Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was $1.66M.
- C4 Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was -$122.00K.
- C4 Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-12-31 was $2.26M, a 7964.29% increase year-over-year.
- C4 Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was $572.00K.
- C4 Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2025 was -$1.14M, a 126.43% decline from fiscal 2024.
- C4 Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2024 was $4.33M.
- C4 Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2023 was -$2.72M.
- C4 Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2022 was -$388.00K, a 106.34% decline from fiscal 2021.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $1.54M 10-Q · filed 2026-08-11 | $3.79M derived: sum of 3 quarters · filed 2026-08-11 | $4.37M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | -$122.00K 10-Q · filed 2026-05-12 | $2.14M derived: sum of 2 quarters · filed 2026-05-12 | $2.71M derived: sum of 3 quarters · filed 2026-05-12 | -$925.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $2.26M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $2.83M derived: sum of 2 quarters · filed 2026-02-26 | -$803.00K derived: sum of 3 quarters · filed 2026-08-11 | -$1.14M 10-K · filed 2026-02-26 |
| 2025-09-30 | $572.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$3.06M derived: sum of 2 quarters · filed 2026-08-11 | -$3.40M 10-Q · filed 2025-11-06 | -$3.37M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | -$3.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$3.97M 10-Q · filed 2026-08-11 | -$3.95M derived: sum of 3 quarters · filed 2026-08-11 | -$4.76M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | -$341.00K 10-Q · filed 2026-05-12 | -$313.00K derived: sum of 2 quarters · filed 2026-05-12 | -$1.13M derived: sum of 3 quarters · filed 2026-05-12 | -$683.00K derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $28.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$788.00K derived: sum of 2 quarters · filed 2026-02-26 | -$342.00K derived: sum of 3 quarters · filed 2026-02-26 | $4.33M 10-K · filed 2026-02-26 |
| 2024-09-30 | -$816.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$370.00K derived: sum of 2 quarters · filed 2025-11-06 | $4.30M 10-Q · filed 2025-11-06 | $2.98M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $446.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $5.12M 10-Q · filed 2025-08-07 | $3.80M derived: sum of 3 quarters · filed 2025-08-07 | $4.49M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $4.67M 10-Q · filed 2025-05-07 | $3.35M derived: sum of 2 quarters · filed 2025-05-07 | $4.04M derived: sum of 3 quarters · filed 2025-05-07 | $2.44M derived: sum of 4 quarters · filed 2025-05-07 |
| 2023-12-31 | -$1.32M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$627.00K derived: sum of 2 quarters · filed 2025-02-27 | -$2.23M derived: sum of 3 quarters · filed 2025-02-27 | -$2.72M 10-K · filed 2025-02-27 |
| 2023-09-30 | $692.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | -$906.00K derived: sum of 2 quarters · filed 2024-10-31 | -$1.40M 10-Q · filed 2024-10-31 | -$1.57M derived: sum of 4 quarters · filed 2024-10-31 |
| 2023-06-30 | -$1.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | -$2.10M 10-Q · filed 2024-08-01 | -$2.27M derived: sum of 3 quarters · filed 2024-08-01 | -$762.00K derived: sum of 4 quarters · filed 2024-08-01 |
| 2023-03-31 | -$498.00K 10-Q · filed 2024-05-08 | -$669.00K derived: sum of 2 quarters · filed 2024-05-08 | $836.00K derived: sum of 3 quarters · filed 2024-05-08 | -$577.00K derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | -$171.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $1.33M derived: sum of 2 quarters · filed 2024-02-22 | -$79.00K derived: sum of 3 quarters · filed 2024-02-22 | -$388.00K 10-K · filed 2024-02-22 |
| 2022-09-30 | $1.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01 | $92.00K derived: sum of 2 quarters · filed 2023-11-01 | -$217.00K 10-Q · filed 2023-11-01 | $4.78M derived: sum of 4 quarters · filed 2023-11-01 |
| 2022-06-30 | -$1.41M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$1.72M 10-Q · filed 2023-08-08 | $3.27M derived: sum of 3 quarters · filed 2023-08-08 | $3.21M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | -$309.00K 10-Q · filed 2023-05-04 | $4.69M derived: sum of 2 quarters · filed 2023-05-04 | $4.63M derived: sum of 3 quarters · filed 2023-05-04 | $5.77M derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | $5.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $4.93M derived: sum of 2 quarters · filed 2023-02-23 | $6.08M derived: sum of 3 quarters · filed 2023-02-23 | $6.12M 10-K · filed 2023-02-23 |
| 2021-09-30 | -$61.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $1.08M derived: sum of 2 quarters · filed 2022-11-03 | $1.12M 10-Q · filed 2022-11-03 | $2.58M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | $1.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $1.18M 10-Q · filed 2022-08-04 | $2.64M derived: sum of 3 quarters · filed 2022-08-04 | $2.79M derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | $40.00K 10-Q · filed 2022-05-05 | $1.50M derived: sum of 2 quarters · filed 2022-05-05 | $1.65M derived: sum of 3 quarters · filed 2022-05-05 | $3.02M derived: sum of 4 quarters · filed 2022-05-05 |
| 2020-12-31 | $1.46M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $1.61M derived: sum of 2 quarters · filed 2022-02-24 | $2.98M derived: sum of 3 quarters · filed 2022-02-24 | $3.26M 10-K · filed 2022-02-24 |
| 2020-09-30 | $147.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $1.52M derived: sum of 2 quarters · filed 2021-11-10 | $1.80M 10-Q · filed 2021-11-10 | $1.96M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | $1.37M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | $1.65M 10-Q · filed 2021-08-11 | $1.81M derived: sum of 3 quarters · filed 2022-02-24 | |
| 2020-03-31 | $281.00K 10-Q · filed 2021-05-13 | $440.00K derived: sum of 2 quarters · filed 2022-02-24 | ||
| 2019-12-31 | $159.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $814.00K 10-K · filed 2022-02-24 | ||
| 2019-09-30 | $655.00K 10-Q · filed 2020-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |